Developer docs
API playgroundTry for free, no card

Search company profiles

CanBas

Full company profile

uuid003a3vo

Namestring
CanBas
Legal namestring
株式会社キャンバス
Websiteurl
canbas.co.jp
Company typeenum
Public
Founded yearint
2000
Descriptiontext

CanBas Co., Ltd. (株式会社キャンバス) is a Japan-based clinical-stage biopharmaceutical company founded in 2000 and listed on the Tokyo Stock Exchange Growth Market (ticker: 4575). The company is headquartered in Numazu, Shizuoka, and operates with a lean team of 11-50 employees focused exclusively on discovering and developing anticancer agents with reduced side-effect profiles. CanBas's lead clinical asset is CBP501, a peptide-based immunogenic cell death inducer designed for triple-combination therapy with cisplatin and nivolumab in third-line metastatic pancreatic cancer; Phase 2 results demonstrated median overall survival of 6.3 months versus approximately 3 months for standard of care, supporting a 2027 commercial launch target. The company's second clinical asset, CBS9106 (SL-801), is a reversible XPO1 inhibitor licensed to Stemline Therapeutics (now part of Menarini Group) for global development, with the program recently pivoted from hematologic malignancies to solid tumor indications. Preclinical pipeline includes next-generation peptides (CBP-A08, CBT005), CBP-A and CBP-B series candidates, and an IDO/TDO inhibitor under joint research with Shizuoka University of Technology.

CanBas monetizes primarily through licensing royalties and technical advisory fees from its CBS9106 partnership with Stemline/Menarini, generating approximately 27-55 million yen per quarter. The company has no product sales revenue and is funded via public equity markets, having raised approximately 4.4 billion yen across two financing rounds in September 2021 (17th share subscription rights and 4th convertible bonds) and November 2022 (full exercise of 17th share subscription rights). GTM is sales-led with a focus on out-licensing pipeline assets to pharmaceutical partners for global commercialization while advancing proprietary candidates through clinical milestones. Customer segments split between pharmaceutical partners (licensing/collaboration) and, post-approval, oncology patients — particularly those with pancreatic adenocarcinoma (approximately 50,000 new US cases annually, with 10,000+ eligible for third-line treatment).

The company's competitive position is anchored by FDA Orphan Drug Designation for CBP501 (granted January 2023, providing up to 7 years of US market exclusivity post-approval), proprietary use patent WO2014/207556 (extended through 2028), and a proprietary cell cycle phenotype screening platform that originated CBP501. Key risks include single-asset revenue concentration on CBS9106 advisory fees, European Phase 3 trial delays stemming from EU manufacturing compliance issues (November 2024), pre-commercial revenue profile with cumulative net losses, and the binary nature of clinical-stage biotech execution on the lead Phase 3 program.

Short descriptiontext

CanBas Co., Ltd. (株式会社キャンバス) is a Japanese clinical-stage biopharmaceutical company developing peptide-based anticancer agents with reduced side effects, led by CBP501 (Phase 2/3) for third-line metastatic pancreatic cancer in triple-combination therapy, with a secondary asset licensed to Stemline/Menarini.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNumazu, Japan
HQ citystring
Numazu
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
anticancer drug development, peptide therapeutics, clinical-stage oncology, cancer immunotherapy, drug discovery pipeline
Industry2 codes
PRIMARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Oncology Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1技術アドバイザリーフィー収益
TypeLicensing Royalties
Description

Stemline社とのCBS9106(SL-801)ライセンス契約に基づき、技術アドバイザリー業務に対する報酬として四半期ごとに収益を受領している。契約開始から4年間のほぼ安定的な収益源。

canbas.co.jp
2抗がん剤上市による製品売上手柄
TypeHardware Sales
Description

抗がん剤の承認・上市が実現した場合、薬剤販売による収益を見込む。上市目標は2027年。

canbas.co.jp
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components2 values
Technology or R&D, Personnel
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1CBP501 (免疫着火剤)
Description

Lead pipeline compound - an immune stimulant (immunological igniter) developed by CanBas, used in combination with cisplatin and nivolumab for cancer treatment.

canbas.co.jp
+1 more record
Core offering1 text field

CanBas is a drug-discovery biotech company that researches and develops anticancer drugs with fewer side effects, leveraging a proprietary cell cycle phenotype screening method. Its lead clinical-stage candidate CBP501 is a peptide-based immune activator being evaluated in Phase 2 trials as a triple-combination therapy (CBP501 + cisplatin + nivolumab) for metastatic pancreatic cancer. A second clinical asset, CBS9106 (reversible XPO1 inhibitor), has been out-licensed to Stemline/Menarini for solid tumor development, with additional preclinical candidates in CBP-A, CBP-B, and IDO/TDO inhibitor series.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 転移性膵臓腺がん3次治療における全生存期間中央値6.3ヶ月(3剤併用群1群)— 現行治療約3ヶ月の約2.1倍
+2 more records
Product overview1 text field

CanBas is a drug-discovery biotech company developing a pipeline of anticancer agents led by two clinical-stage candidates. CBP501 (immune activator) is in Phase 2 clinical trials in the US and Europe for third-line metastatic pancreatic cancer, administered as a triple-combination therapy (CBP501 + cisplatin + nivolumab). CBS9106 (reversible XPO1 inhibitor) is in solid tumor development following a shift away from hematologic malignancies. The preclinical pipeline includes the CBP-A series (next-generation peptides related to CBP501), CBP-B series (immune suppression reversal mechanism), an IDO/TDO inhibitor, and additional NEXT-stage projects in early research.

Product and service7 records
1CBP501 (Immune Activator / Immunological Ignition Agent)
CategoryClinical-stage oncology drug candidate
Description

Peptide-based anticancer agent functioning as an immune activator (immunological ignition agent). CBP501 enhances the anticancer effects of platinum-based drugs by promoting their influx into cancer cells through direct contact with calmodulin, and activates anticancer immunity via effects on macrophages in the tumor microenvironment. Administered as triple-combination therapy with cisplatin and nivolumab for third-line metastatic pancreatic cancer. In Phase 2 clinical trials with FDA Orphan Drug Designation.

2CBS9106 (Reversible XPO1 Inhibitor, development code SL-801)
CategoryClinical-stage oncology drug candidate (licensed)
Description

Reversible XPO1 (Exportin 1) inhibitor low-molecular-weight compound developed for solid tumors. Originally investigated for hematologic malignancies (multiple myeloma) under Stemline Therapeutics, with development subsequently shifted to solid tumor indications including colorectal cancer, KRAS-mutant cancers, renal cell carcinoma, and p53-associated cancers in combination with other anticancer agents. Out-licensed globally to Stemline/Menarini.

3CBP-A Series Peptides (Preclinical Pipeline)
CategoryPreclinical oncology pipeline
Description

Peptide-type anticancer agent candidates belonging to the same lineage as the original peptide TAT-S216 and its optimized derivative CBP501. Development candidate selection is ongoing.

4CBP-B Series Peptides (Preclinical Pipeline)
5IDO/TDO Inhibitor
6CBP-A08 (Next-Generation Peptide Anticancer Agent)
7CBT005 (Next-Generation Immune Activation Anticancer Agent)
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2014-12-26
Description

CBS9106(開発コードSL-801)の全世界における独占的ライセンス契約を締結。Stemline社は进行固形癌対象臨床第1相試験を実施し、ESMO2020での発表後は血液がんから固形がん対象开发にシフト。Menarini GroupによるStemline買収後も開発は継続される。同社로부터技術アドバイザリーフィーを四半期ごとに受領(27〜55百万円/年程度)。

2NEDO(国立研究開発法人新エネルギー・産業技術総合開発機構)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

CBP501の製造法改良に関する補助事业を実施。承認されても大丈夫な製造法を既に確立するに至った。

canbas.co.jp
3静岡県立大学
Strategic tierMinorTypeStrategic or Co-development Partner
Description

IDO/TDO阻害剂の共同研究を実施。COVID-19重症患者におけるサイトカインストーム抑制作用の研究にも関連する。

canbas.co.jp
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Italian pharma group that acquired Stemline Therapeutics (the licensee of CanBas's CBS9106/SL-801). Comparable as the indirect commercial partner and existing royalty payer for CanBas's out-licensed XPO1 inhibitor asset.

2NanoCarrier
TypeDirect peer
Description

Japanese oncology-focused biotech developing polymeric micelle drug delivery for cancer. Comparable as a small Japanese pre-commercial oncology company pursuing novel mechanisms with TSE listing and similar scale.

3PeptiDream
TypeDirect peer
Description

Japanese peptide-based drug discovery biotech listed on TSE Prime. Directly comparable to CanBas in using proprietary peptide platforms to develop constrained/peptidic therapeutics, including oncology candidates, with a similar small-cap, Japan-listed profile.

TypeEmerging player
Description

Clinical-stage immuno-oncology company developing novel computational-predicted drug targets for combinations with checkpoint inhibitors. Comparable as a clinical developer focused on immune-modulating combinations in oncology.

TypeBroad incumbent
Description

Japan's leading oncology-focused pharmaceutical company with established anticancer franchise (Lonsurf, Teysuno). Comparable as the dominant Japanese oncology player that new immune-oncology assets like CBP501 would ultimately compete against or partner with.

6Ono Pharmaceutical
TypeBroad incumbent
Description

Japan-based pharma that developed and commercializes nivolumab (Opdivo), the checkpoint inhibitor used in CanBas's triple-combination regimen. Highly comparable strategic partner/customer as the IO backbone supplier for CBP501 therapy.

TypeEmerging player
Description

Clinical-stage oncology biotech focused on targeted immuno-oncology combinations (KRAS inhibitors). Comparable as a smaller-scale oncology combination-therapy developer whose pivot through Phase 2/3 mirrors CanBas's risk profile.

TypeBroad incumbent
Description

Major Japanese pharmaceutical company with significant oncology pipeline including ADC franchise (Enhertu). Comparable as a large Japanese oncology incumbent that could acquire or partner with promising Japanese biotechs in oncology.

9Chugai Pharmaceutical
TypeBroad incumbent
Description

Japanese pharma leader with major oncology portfolio and biotech R&D heritage (Roche subsidiary). Comparable as the benchmark large-cap Japanese oncology innovator, useful for valuation and partnership framework reference.

TypeBroad incumbent
Description

Large Japanese global pharmaceutical company with oncology in its portfolio (Xtandi, Padcev). Comparable as an established Japanese oncology player that could be a potential acquirer of CanBas or commercial partner for pancreatic assets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CanBas

Oncology Pharmaceuticalscanbas.co.jp

CanBas Co., Ltd. (株式会社キャンバス) is a Japanese clinical-stage biopharmaceutical company developing peptide-based anticancer agents with reduced side effects, led by CBP501 (Phase 2/3) for third-line metastatic pancreatic cancer in triple-combination therapy, with a secondary asset licensed to Stemline/Menarini.

What CanBas does

CanBas Co., Ltd. (株式会社キャンバス) is a Japan-based clinical-stage biopharmaceutical company founded in 2000 and listed on the Tokyo Stock Exchange Growth Market (ticker: 4575). The company is headquartered in Numazu, Shizuoka, and operates with a lean team of 11-50 employees focused exclusively on discovering and developing anticancer agents with reduced side-effect profiles. CanBas's lead clinical asset is CBP501, a peptide-based immunogenic cell death inducer designed for triple-combination therapy with cisplatin and nivolumab in third-line metastatic pancreatic cancer; Phase 2 results demonstrated median overall survival of 6.3 months versus approximately 3 months for standard of care, supporting a 2027 commercial launch target. The company's second clinical asset, CBS9106 (SL-801), is a reversible XPO1 inhibitor licensed to Stemline Therapeutics (now part of Menarini Group) for global development, with the program recently pivoted from hematologic malignancies to solid tumor indications. Preclinical pipeline includes next-generation peptides (CBP-A08, CBT005), CBP-A and CBP-B series candidates, and an IDO/TDO inhibitor under joint research with Shizuoka University of Technology.

CanBas monetizes primarily through licensing royalties and technical advisory fees from its CBS9106 partnership with Stemline/Menarini, generating approximately 27-55 million yen per quarter. The company has no product sales revenue and is funded via public equity markets, having raised approximately 4.4 billion yen across two financing rounds in September 2021 (17th share subscription rights and 4th convertible bonds) and November 2022 (full exercise of 17th share subscription rights). GTM is sales-led with a focus on out-licensing pipeline assets to pharmaceutical partners for global commercialization while advancing proprietary candidates through clinical milestones. Customer segments split between pharmaceutical partners (licensing/collaboration) and, post-approval, oncology patients — particularly those with pancreatic adenocarcinoma (approximately 50,000 new US cases annually, with 10,000+ eligible for third-line treatment).

The company's competitive position is anchored by FDA Orphan Drug Designation for CBP501 (granted January 2023, providing up to 7 years of US market exclusivity post-approval), proprietary use patent WO2014/207556 (extended through 2028), and a proprietary cell cycle phenotype screening platform that originated CBP501. Key risks include single-asset revenue concentration on CBS9106 advisory fees, European Phase 3 trial delays stemming from EU manufacturing compliance issues (November 2024), pre-commercial revenue profile with cumulative net losses, and the binary nature of clinical-stage biotech execution on the lead Phase 3 program.

CanBas firmographics

Firmographics
Name
CanBas
Legal name
株式会社キャンバス
Website
https://canbas.co.jp
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
1–10 employees
Short description
CanBas Co., Ltd. (株式会社キャンバス) is a Japanese clinical-stage biopharmaceutical company developing peptide-based anticancer agents with reduced side effects, led by CBP501 (Phase 2/3) for third-line metastatic pancreatic cancer in triple-combination therapy, with a secondary asset licensed to Stemline/Menarini.
Ownership category
akta.pro rank

CanBas industry classification

Industry
Product category
Oncology Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Anticancer drug development
  • Peptide therapeutics
  • Clinical-stage oncology
  • Cancer immunotherapy
  • Drug discovery pipeline

Where CanBas is headquartered

Location

Headquarters

HQ city
Numazu
HQ country
Japan
HQ region
Asia

Offices1 record

Markets served

CanBas business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel

Revenue model

  1. 技術アドバイザリーフィー収益: Stemline社とのCBS9106(SL-801)ライセンス契約に基づき、技術アドバイザリー業務に対する報酬として四半期ごとに収益を受領している。契約開始から4年間のほぼ安定的な収益源。
  2. 抗がん剤上市による製品売上手柄: 抗がん剤の承認・上市が実現した場合、薬剤販売による収益を見込む。上市目標は2027年。

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

CanBas product offering

Product offering

Core offering

CanBas is a drug-discovery biotech company that researches and develops anticancer drugs with fewer side effects, leveraging a proprietary cell cycle phenotype screening method. Its lead clinical-stage candidate CBP501 is a peptide-based immune activator being evaluated in Phase 2 trials as a triple-combination therapy (CBP501 + cisplatin + nivolumab) for metastatic pancreatic cancer. A second clinical asset, CBS9106 (reversible XPO1 inhibitor), has been out-licensed to Stemline/Menarini for solid tumor development, with additional preclinical candidates in CBP-A, CBP-B, and IDO/TDO inhibitor series.

Product overview

CanBas is a drug-discovery biotech company developing a pipeline of anticancer agents led by two clinical-stage candidates. CBP501 (immune activator) is in Phase 2 clinical trials in the US and Europe for third-line metastatic pancreatic cancer, administered as a triple-combination therapy (CBP501 + cisplatin + nivolumab). CBS9106 (reversible XPO1 inhibitor) is in solid tumor development following a shift away from hematologic malignancies. The preclinical pipeline includes the CBP-A series (next-generation peptides related to CBP501), CBP-B series (immune suppression reversal mechanism), an IDO/TDO inhibitor, and additional NEXT-stage projects in early research.

Differentiator

Problem solved

Functional benefit

Brands

  • CBP501 (免疫着火剤): Lead pipeline compound - an immune stimulant (immunological igniter) developed by CanBas, used in combination with cisplatin and nivolumab for cancer treatment.
  • CBS9106 (可逆的XPO1阻害剤)

Products and services

  • CBP501 (Immune Activator / Immunological Ignition Agent) Peptide-based anticancer agent functioning as an immune activator (immunological ignition agent). CBP501 enhances the anticancer effects of platinum-based drugs by promoting their influx into cancer cells through direct contact with calmodulin, and activates anticancer immunity via effects on macrophages in the tumor microenvironment. Administered as triple-combination therapy with cisplatin and nivolumab for third-line metastatic pancreatic cancer. In Phase 2 clinical trials with FDA Orphan Drug Designation.
  • CBS9106 (Reversible XPO1 Inhibitor, development code SL-801) Reversible XPO1 (Exportin 1) inhibitor low-molecular-weight compound developed for solid tumors. Originally investigated for hematologic malignancies (multiple myeloma) under Stemline Therapeutics, with development subsequently shifted to solid tumor indications including colorectal cancer, KRAS-mutant cancers, renal cell carcinoma, and p53-associated cancers in combination with other anticancer agents. Out-licensed globally to Stemline/Menarini.
  • CBP-A Series Peptides (Preclinical Pipeline) Peptide-type anticancer agent candidates belonging to the same lineage as the original peptide TAT-S216 and its optimized derivative CBP501. Development candidate selection is ongoing.
  • CBP-B Series Peptides (Preclinical Pipeline)
  • IDO/TDO Inhibitor
  • CBP-A08 (Next-Generation Peptide Anticancer Agent)
  • CBT005 (Next-Generation Immune Activation Anticancer Agent)

Quantifiable outcome

  • 転移性膵臓腺がん3次治療における全生存期間中央値6.3ヶ月(3剤併用群1群)— 現行治療約3ヶ月の約2.1倍
  • +2 more outcomes

Companies that use CanBas

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles3 records

CanBas technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

CanBas partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Stemline Therapeutics社(Menarini Group傘下)coreOEM/ Whitelabel/ Licensing Partner · 26 December 2014CBS9106(開発コードSL-801)の全世界における独占的ライセンス契約を締結。Stemline社は进行固形癌対象臨床第1相試験を実施し、ESMO2020での発表後は血液がんから固形がん対象开发にシフト。Menarini GroupによるStemline買収後も開発は継続される。同社로부터技術アドバイザリーフィーを四半期ごとに受領(27〜55百万円/年程度)。
  • NEDO(国立研究開発法人新エネルギー・産業技術総合開発機構)minorStrategic or Co-development PartnerCBP501の製造法改良に関する補助事业を実施。承認されても大丈夫な製造法を既に確立するに至った。
  • 静岡県立大学minorStrategic or Co-development PartnerIDO/TDO阻害剂の共同研究を実施。COVID-19重症患者におけるサイトカインストーム抑制作用の研究にも関連する。

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

CanBas competitors and assessment

Company assessment

Others

  • Menarini Group: Italian pharma group that acquired Stemline Therapeutics (the licensee of CanBas's CBS9106/SL-801). Comparable as the indirect commercial partner and existing royalty payer for CanBas's out-licensed XPO1 inhibitor asset.

Direct peers

  • NanoCarrier: Japanese oncology-focused biotech developing polymeric micelle drug delivery for cancer. Comparable as a small Japanese pre-commercial oncology company pursuing novel mechanisms with TSE listing and similar scale.
  • PeptiDream: Japanese peptide-based drug discovery biotech listed on TSE Prime. Directly comparable to CanBas in using proprietary peptide platforms to develop constrained/peptidic therapeutics, including oncology candidates, with a similar small-cap, Japan-listed profile.

Emerging players

  • Compugen: Clinical-stage immuno-oncology company developing novel computational-predicted drug targets for combinations with checkpoint inhibitors. Comparable as a clinical developer focused on immune-modulating combinations in oncology.
  • Mirati Therapeutics: Clinical-stage oncology biotech focused on targeted immuno-oncology combinations (KRAS inhibitors). Comparable as a smaller-scale oncology combination-therapy developer whose pivot through Phase 2/3 mirrors CanBas's risk profile.

Broad incumbents

  • Taiho Pharmaceutical: Japan's leading oncology-focused pharmaceutical company with established anticancer franchise (Lonsurf, Teysuno). Comparable as the dominant Japanese oncology player that new immune-oncology assets like CBP501 would ultimately compete against or partner with.
  • Ono Pharmaceutical: Japan-based pharma that developed and commercializes nivolumab (Opdivo), the checkpoint inhibitor used in CanBas's triple-combination regimen. Highly comparable strategic partner/customer as the IO backbone supplier for CBP501 therapy.
  • Daiichi Sankyo: Major Japanese pharmaceutical company with significant oncology pipeline including ADC franchise (Enhertu). Comparable as a large Japanese oncology incumbent that could acquire or partner with promising Japanese biotechs in oncology.
  • Chugai Pharmaceutical: Japanese pharma leader with major oncology portfolio and biotech R&D heritage (Roche subsidiary). Comparable as the benchmark large-cap Japanese oncology innovator, useful for valuation and partnership framework reference.
  • Astellas Pharma: Large Japanese global pharmaceutical company with oncology in its portfolio (Xtandi, Padcev). Comparable as an established Japanese oncology player that could be a potential acquirer of CanBas or commercial partner for pancreatic assets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

CanBas social profiles

Digital presence

CanBas compliance and trust

Trust signal

Compliance1 record

CanBas financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CanBas leadership team

Management profile

Number of profiles

Profiles1 record

CanBas funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CanBas M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CanBas

What does CanBas do?

CanBas is a drug-discovery biotech company that researches and develops anticancer drugs with fewer side effects, leveraging a proprietary cell cycle phenotype screening method. Its lead clinical-stage candidate CBP501 is a peptide-based immune activator being evaluated in Phase 2 trials as a triple-combination therapy (CBP501 + cisplatin + nivolumab) for metastatic pancreatic cancer. A second clinical asset, CBS9106 (reversible XPO1 inhibitor), has been out-licensed to Stemline/Menarini for solid tumor development, with additional preclinical candidates in CBP-A, CBP-B, and IDO/TDO inhibitor series.

Is CanBas a public or private company?

CanBas is a public company. It is classified as public and is currently operating.

When was CanBas founded?

CanBas was founded in 2000. It employs 1 to 10 people.

Where is CanBas based?

CanBas is headquartered in Numazu, Japan, in the Asia region.

How does CanBas make money?

Two revenue lines are on record. 技術アドバイザリーフィー収益 is the primary driver. The others are 抗がん剤上市による製品売上手柄.

Who are CanBas's main competitors?

Menarini Group is listed as an others. Direct peers are NanoCarrier and PeptiDream. Emerging players are Compugen and Mirati Therapeutics. Broad incumbents are Taiho Pharmaceutical, Ono Pharmaceutical, Daiichi Sankyo, Chugai Pharmaceutical and Astellas Pharma.

Does CanBas have an API?

No public API is recorded for CanBas.

What industry is CanBas in?

CanBas's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIAIAC, Rare Oncology & Hematologic Malignancy Therapies, with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales